Searchable abstracts of presentations at key conferences in endocrinology

ea0032p169 | Calcium and Vitamin D metabolism | ECE2013

Impact of vitamin deficiency and oF GH–IGF1 on cardiovascular risk in hypopituitaric patients

Savanelli Maria Cristina , Scarano Elisabetta , Vuolo Laura , Brunelli Vincenzo , Rubino Manila , Colao Annamaria , Di Somma Carolina

To determine a correlation between Vitamin D, GH, IGF1 and cardiovascular risk we enrolled. 41 GHD patients (22 M, 19 F, age 18–84 years) and 41 controls. In all we determined: anthropometric parameters, blood pressure (BP), lipid and glucose profile, PTH, 25-OH-vitamin D, GH peak after GHRH+ARG, IGF1. Metabolic syndrome (MS) was evaluated by the IDF criteria.The vitamin D were lower in patients than in controls (21.3±12.3 vs 28.2±9.4, <em...

ea0081p313 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Obesity and obesity-related diseases as a new clinical features in 3q27.3 microdeletion syndrome involving adipoq gene: a case study

De Brasi Davide , Novizio Vincenzo , Barba Livia , Scarano Elisabetta , Serino Domenico , Novizio Roberto , Della Monica Matteo , Petillo Roberta , Scavuzzo Francesco

Introduction: Adipose tissue is recognized as an important endocrine organ, secreting many endocrine factors. Adiponectin is the most abundant peptide released into circulation, encoded by ADIPOQ gene localized in chromosome 3q27.3. Adiponectin decreases intracellular ceramide, implicated in insulin resistance, inflammation and atherosclerosis. It stimulates fatty acid oxidation in skeletal muscle and inhibits glucose production in the liver. Hypo-adiponectinemia plays a centr...

ea0022p511 | Growth factors | ECE2010

IGF1 and IGFBP3 levels in relapsing-remitting and secondary progressive multiple sclerosis (MP)

Di Somma Carolina , Lanzillo Roberta , Savanelli Maria Cristina , Scarano Elisabetta , Contaldi Paola , Lombardi Gaetano , Morra Vincenzo Brescia , Colao Annamaria

Background: There is a growing body of evidence of an alteration in GH/IGF1 axis in neurological diseases. IGF1 and IGFBP3 serum levels are reported to be similar in controls, relapsing remitting (RR) MS and primary progressive (PP) MS patients, but in RR patients on IFN therapy they were found to be higher then in controls. IGFBP3 was found to correlate to progression index in PPMS.Objective: To compare IGF1 and IGFBP3 serum levels in RR MS and secondar...